SCHEMBL5464580

SCHEMBL5464580

COc1cc(Nc2ncc(-c3ccc(F)cc3)o2)cc(OC)c1OC

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 5/20 0.77
FLT4 P35916 5/20 0.77
KDR P35968 5/20 0.77
ALOX5 P09917 1/20 0.62
IMPDH2 P12268 7/20 0.53
BRAF P15056 1/20 0.52
PLK1 P53350 1/20 0.49
RPS6KA2 Q15349 1/20 0.47
TUBB4A P04350 1/20 0.47
TUBB P07437 1/20 0.47
TUBA3C P0DPH7 1/20 0.47
TUBA1B P68363 1/20 0.47
TUBA4A P68366 1/20 0.47
TUBB4B P68371 1/20 0.47
TUBB3 Q13509 1/20 0.47
TUBB2A Q13885 1/20 0.47
TUBB8 Q3ZCM7 1/20 0.47
TUBA3E Q6PEY2 1/20 0.47
TUBA1A Q71U36 1/20 0.47
TUBA1C Q9BQE3 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5469587 0.88 KDR (0.76) FLT1FLT4KDRALOX5IMPDH2
Gw627512B SCHEMBL5477421 0.87 KDR (1.00) FLT1FLT4KDRIMPDH2VCP
SCHEMBL5469672 0.81 KDR (0.86) FLT1FLT4KDRIMPDH2VCP
SCHEMBL5230845 0.80 KDR (0.76) FLT1FLT4KDRIMPDH2PLK1
SCHEMBL5464876 0.76 FLT1 (0.77) FLT1FLT4KDRALOX5IMPDH2
SCHEMBL5319878 0.75 FLT1 (0.76) FLT1FLT4KDRALOX5IMPDH2
SCHEMBL22925625 0.75 ALOX5 (0.66) FLT1FLT4KDRALOX5IMPDH2
SCHEMBL5480404 0.74 KDR (0.97) FLT1FLT4KDRIMPDH2VCP
SCHEMBL21303759 0.74 ALOX5 (0.58) FLT1FLT4KDRALOX5VCP
SCHEMBL20242287 0.74 ALOX5 (0.61) FLT1FLT4KDRALOX5IMPDH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7189712-B2 1,3-Oxazole compounds for the treatment of cancer SMITHKLINE BEECHAM CORPORATION (US) 2007-03-13 US claimed
US-20050288515-A1 Chemical compounds SMITHLINE BEECHAM CORPORATION 2005-12-29 US claimed
US-20070142437-A1 CHEMICAL COMPOUNDS BROWN MATTHEW L 2007-06-21 US disclosed
US-20070142437-A1 CHEMICAL COMPOUNDS BROWN MATTHEW L 2007-06-21 US disclosed
US-20070142437-A1 CHEMICAL COMPOUNDS BROWN MATTHEW L 2007-06-21 US disclosed
US-7189712-B2 1,3-Oxazole compounds for the treatment of cancer SMITHKLINE BEECHAM CORPORATION (US) 2007-03-13 US disclosed
US-7189712-B2 1,3-Oxazole compounds for the treatment of cancer SMITHKLINE BEECHAM CORPORATION (US) 2007-03-13 US disclosed
US-7189712-B2 1,3-Oxazole compounds for the treatment of cancer SMITHKLINE BEECHAM CORPORATION (US) 2007-03-13 US disclosed
US-20050288515-A1 Chemical compounds SMITHLINE BEECHAM CORPORATION 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142437-A1 CHEMICAL COMPOUNDS CDK4, CDK2, CDK3 FLT1 56/4885FLT4 47/4885KDR 33/4885
US-20050288515-A1 Chemical compounds CDK4, CDK2, CDK3 FLT1 56/4885FLT4 47/4885KDR 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.